Novo Nordisk A/S (NONOF)
OTCMKTS · Delayed Price · Currency is USD
49.02
-0.98 (-1.96%)
Oct 31, 2025, 4:00 PM EDT
Novo Nordisk Revenue
Novo Nordisk had revenue of 76.86B DKK in the quarter ending June 30, 2025, with 12.93% growth. This brings the company's revenue in the last twelve months to 311.94B, up 20.90% year-over-year. In the year 2024, Novo Nordisk had annual revenue of 290.40B with 25.03% growth.
Revenue (ttm)
311.94B DKK
Revenue Growth
+20.90%
P/S Ratio
4.42
Revenue / Employee
4.03M DKK
Employees
77,349
Market Cap
216.87B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 290.40B | 58.14B | 25.03% |
| Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
| Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
| Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
| Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| China New Energy Group Co. | 12.51M |
| Northwest Biotherapeutics | 1.09M |
Novo Nordisk News
- 18 hours ago - Global week ahead: Is Novo Nordisk past 'peak uncertainty'? - CNBC
- 1 day ago - Pfizer Sues Rivals Metsera, Novo Nordisk Over Alleged Interference in Merger Talks - IBTimes
- 1 day ago - Pfizer sues to block Novo Nordisk's bid for Metsera in high-stakes pharma clash - Invezz
- 2 days ago - Pfizer sues Metsera, Novo Nordisk over rival obesity drug bid - CNBC
- 2 days ago - Pfizer Sues Novo Nordisk And Metsera To Block The Proposed $6.5 Billion Deal - Investor's Business Daily
- 2 days ago - Novo Nordisk (NVO) in Pursuit of Metsera Amid Pfizer's Regulatory Progress - GuruFocus
- 2 days ago - Pfizer has filed a lawsuit seeking to block Novo Nordisk from circumventing Pfizer's deal for weight-loss drug startup Metsera - WSJ
- 2 days ago - Pfizer sues Metsera, Novo Nordisk over breach of merger deal - Reuters